Faralimomab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 457121809

| type = mab

| mab_type = mab

| source = o

| target = Interferon receptor

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 167816-91-3

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 8MK3PL8DNZ

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Faralimomab is a mouse monoclonal antibody and an immunomodulator.{{Cite web |url=http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list76.pdf |title=WHO Drug Information |access-date=2009-09-24 |archive-url=https://web.archive.org/web/20110604232719/http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list76.pdf |archive-date=2011-06-04 |url-status=dead }}{{cite book | vauthors = Pelletier JP, Mukhtar F | chapter = Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies | veditors = Maitta RW |title=Immunologic Concepts in Transfusion Medicine |date=2020 |publisher=Elsevier |location=Philadelphia |isbn=978-0-323-67510-9 | doi = 10.1016/B978-0-323-67509-3.00016-0 |page=286| s2cid = 213508934 }}